Les anti-inflammatoires non stéroïdiens doivent-ils être utilisés de manière continue dans la spondylarthrite ankylosante ? ☆

[1]  D. Wendling.  Do non-steroidal anti-inflammatory drugs have disease-modifying effects in spondyloarthritis? , 2013, Joint, bone, spine : revue du rhumatisme.

[2]  S. Mathieu,et al.  Vascular effects of nonsteroidal antiinflammatory drugs. , 2013, Joint, bone, spine : revue du rhumatisme.

[3]  M. Dougados,et al.  Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis , 2012, Annals of the rheumatic diseases.

[4]  E. Märker-Hermann,et al.  Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort , 2012, Annals of the rheumatic diseases.

[5]  M. Dougados,et al.  Treatment of Osteoarthritis with Continuous Versus Intermittent Celecoxib , 2011, The Journal of Rheumatology.

[6]  M. Dougados,et al.  2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis , 2011, Annals of the rheumatic diseases.

[7]  M. Dougados,et al.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2011, Annals of the rheumatic diseases.

[8]  M. Egger,et al.  Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis , 2011, BMJ : British Medical Journal.

[9]  L. G. García Rodríguez,et al.  Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. , 2010, Arthritis and rheumatism.

[10]  P. Geusens,et al.  A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip , 2006, Annals of the rheumatic diseases.

[11]  M. Dougados,et al.  Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. , 2005, Arthritis and rheumatism.

[12]  M. Dougados,et al.  Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. , 2005, Arthritis and rheumatism.

[13]  M. Dougados,et al.  What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. , 2004, Arthritis and rheumatism.

[14]  E. Schwarz,et al.  Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. , 2002, The Journal of clinical investigation.

[15]  M. Dougados,et al.  Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. , 2001, Arthritis and rheumatism.

[16]  D. Henry,et al.  Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. , 2003, British journal of clinical pharmacology.

[17]  Boersma Jw.  Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. , 1976 .

[18]  A. Calin,et al.  Double-blind Cross-over Trial of Flurbiprofen and Phenylbutazone in Ankylosing Spondylitis , 1974, British medical journal.